Category:Immunotherapy
From WikiMD's Wellness Encyclopedia
This is a category page. It lists all of the pages in category "Immunotherapy" as well as all subcategories of category "Immunotherapy" if any exist.
Pages in category "Immunotherapy"
The following 200 pages are in this category, out of 200 total.
3
A
- Abscopal effect
- Active immunotherapy
- Adecatumumab
- Adegramotide
- Adoptive immunotherapy
- ADXS11-001
- AIM ImmunoTech
- ALECSAT
- Allergy desensitization
- Allergy immunotherapy
- Allergy shots
- ALT-803
- Amatuximab
- AMG 319
- ANA773
- Angus Dalgleish
- Anti-idiotypic vaccine
- Antibody-drug conjugate
- Antigen-presenting cell vaccine
- Apolizumab
- Artificial antigen presenting cells
- Ascrinvacumab
- Aselizumab
- Autologous immune enhancement therapy
- Autologous patient-specific tumor antigen response
- Autologous tumor cell
- AVATAR
- AVICINE
- Avicine
B
C
- Camrelizumab
- Cancer immunology
- Cancer immunotherapy
- Cancer vaccine
- Cancer vaccine targeting CD4+ T cells
- CancerVax
- CAR T cell
- CAR T-cell therapy
- CAR-301,060
- Cellectis
- Cellular adoptive immunotherapy
- Checkpoint inhibitor induced colitis
- Chimeric antigen receptor
- Chimeric antigen receptor T cell
- Clevegen
- Coley's toxins
- Combinatorial ablation and immunotherapy
- Cryoimmunotherapy
- CTAG1B
- CTLA-4
- CVac
- Cytokine-induced killer cell
- Cytotherapy
- Cytotherapy (journal)
D
E
I
- Ieramilimab
- Igovomab
- IMAB362
- Imjudo
- IMM-101
- ImmTAC
- Immune cell
- Immune checkpoint inhibitor
- Immune stimulating antibody conjugate
- Immune Therapy Holdings
- Immune-Related Response Criteria
- Immunocore
- Immunogen
- Immunoscore
- Immunotoxin
- Immunotoxins
- Immuron
- Immutep
- Indoximod
- Inolimomab
- Interferon alfa-2b
- Iovance Biotherapeutics
- IPI-549
M
P
S
T
- T cell receptor T cell therapy
- T-cell vaccination
- Talquetamab
- Taplitumomab
- Tarlatamab
- Tasquinimod
- Tecemotide
- Telimomab
- Therapeutic vaccines
- Thomas Hutson
- Thrombogenicity
- Thymectacin
- Timeline of immunology
- Tisagenlecleucel-T
- Tislelizumab
- TNB-486
- TOL101
- Tolerogenic therapy
- Tovaxin
- Trifunctional antibody
- TTX-030
- Tumor mutational burden
- Tumor-infiltrating lymphocytes
- Tumour-infiltrating lymphocyte
